ClinicalTrials.gg
CompletedNCT03974399Updated Mar 2, 2021

BDNF Levels After Bacopa

An interventional study of Bacopa Monnieri in Memory, sponsored by Roskamp Institute Inc.. Completed at 1 site in United States. Open to participants aged 60 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Roskamp Institute Inc. · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
60 Years to 78 Years
Sex
All
01

Study summary

Brain-derived neurotrophic factor (BDNF) is a well-known neurotrophic factor important for learning, memory, and synaptogenesis. Healthy activities such as exercise are believed to raise BDNF, while stress is associated with lower BDNF. What is not well understood is if there are certain supplements that may raise BDNF over time. Bacopa monnieri is well characterized nutraceutical. Animal and pre-clinical data support multiple beneficial mechanisms, including raising BDNF and increasing synaptogenesis. Additionally, small studies have shown Bacopa enhances cognition and improves mood. We would like to investigate if BDNF level changes in people after starting Bacopa.

Read the detailed description

This is a single site two-visit, 12-week, open label, trial to evaluate the safety, tolerability, and potential effects of Bacopa on BDNF, MoCA and GDS. Potentially eligible subjects will be invited to screening (Visit 1) at the study site. Subjects will sign an informed consent followed by collection of medical history and history of current medications, have their height, weight, vital signs (blood pressure, pulse, and temperature) measured, complete study assessments (MoCA , BDS and LEC) Routine clinical laboratory tests (hematology and chemistry) will be performed. Blood samples will be taken for analysis of BDNF and genetics (APOE, BDNF).

Subjects will be instructed to orally self-administer the provided supplement (Bacopa) preferably with food with no dietary restrictions once a day in the morning.

Subjects will be contacted by phone at 1 week (+/- 3 days) to be reminded to go to two pills per day, 1 month (+/-1 week) to check on compliance or any AE's and 2 months (+/- 1 week) to report any Adverse events for review by the Principal Investigator.

Subjects will return to the study site for Visit 2 at the end of 12 weeks (+/- 1 week). Study staff will question subjects about any changes in the subject's health since the first visit. They will be asked about their exercise activity and if there have been any changes to their LEC-5. Subjects will have their weight and vital signs measured. Routine clinical laboratory tests (hematology and chemistry) will be performed, and blood samples will be saved for analysis of Bacopa and other biomarkers

02

Conditions studied

  • Memory
03

In context

Lead sponsor

Roskamp Institute Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females of any ethnicity, at 60 to 78 on day of screening.
  2. Have a score of 25 or above on (Montreal Cognitive assessment).
  3. Have a score of 9 or below on GDS (Geriatric Depression Scale)
  4. Provide written .
  5. Be able and willing to follow instructions, participate in study assessments, and be present for the required study visits.
  6. Otherwise stable medical history and general health up to the discrepancy of the PI.

Exclusion criteria

Exclusion Criteria:

  1. Have , allergy, or sensitivity to the study product or their components.
  2. Have any significant illness or condition that could, in the Investigator's or sub-Investigator's opinion, be expected to interfere with the study parameters or study conduct or put the subject at significant risk. These may include but are not limited to: untreated chronic hypertension; receiving chemotherapy; depression requiring medical intervention on a daily basis; myocardial infarction within six months of screening; renal failure; and/or hepatic failure.
  3. Have a current unstable medical condition (e.g., symptomatic uncontrolled diabetes mellitus), or a condition that might affect their ability to participate (e.g., cancer requiring frequent medical visits for chemotherapy).
  4. Have values on standard clinical laboratory assessments that are deemed medically significant (show evidence of untreated significant medical illness or pose a risk of significant intercurrent illness during the study in the opinion of the investigator).
  5. Currently taking any medication classified by the FDA as an anti-depressant or have discontinued one of these types of medications within 30 days of screening.
  6. Currently abusing drugs or alcohol, and/or have a history of drug or alcohol dependence within six months of entering this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Other
    study enrollment

    all participants will take dietary supplement, Bacopa Monnieri, daily for 3 months

    Dietary Supplement: Bacopa Monnieri

Interventions

  • Dietary supplementBacopa Monnieri

    subjects will take Bacopa Monnieri daily for 3 months

06

What researchers measure

Primary outcomes

  1. Changes in Brain Derived neurotrophic factor (BDNF)

    a. Change in BDNF levels

    Time frame: 3 months

  2. Changes in Brain Derived Neurotropic factor (BDNF) signaling pathway

    Change in BDNF signaling pathway

    Time frame: 3 months

Secondary outcomes

  1. Change in Montreal Cognitive Assessment

    Changes in Montreal Cognitive Assessment (MoCA). Score range 0-30.

    Time frame: 3 months

  2. Change in Geriatric Depression Scale

    Change in Geriatric Depression Scale (GDS). Score range 0-15.

    Time frame: 3 months

07

Study locations

1 site
  • The Roskamp Institute, Inc.
    Sarasota, Florida 34243, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Apr 2020, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jun 4, 2019
StartActual
May 30, 2019
Primary completionActual
Apr 1, 2020
CompletionActual
Jun 1, 2020
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03974399
Lead sponsor
Roskamp Institute Inc.
Collaborators
Florida Department of Health
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
May 30, 2019
Primary completion
Apr 1, 2020
Completion
Jun 1, 2020
Last update
Mar 2, 2021

Study contacts

Andrew Keegan, M.D.
principal investigator · The Roskamp Institute Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bacopa monnieri

Start the discussion